Marks start of European commercial rollout of aXess™, bringing it into routine clinical practice Builds on CE mark approval in…
Read More
Xeltis
De Lismortel 31
5612 AR Eindhoven
The Netherlands
info@xeltis.com
+31 40 751 7614
US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world…
Read More
Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary…
Read More
CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule…
Read More
Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m…
Read More
The Journal of Vascular Access. aXess FIH 12m follow-up & clinical histopathology Abstract Background: Xeltis’ aXess hemodialysis (HD) conduit is…
Read More
Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment Primary endpoint met with standout sustained patency…
Read More
Computers in Biology and Medicine. ETR computational modeling validated with Xeltis sheep data
Read More
Preliminary clinical data from Xabg, Xeltis’ coronary artery bypass conduit (CABG), demonstrating positive safety and patency In an earlier, separate…
Read More
Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP)…
Read More